Bausch + Lomb (NYSE:BLCO) Given Hold Rating at Needham & Company LLC

Bausch + Lomb (NYSE:BLCO - Get Free Report)'s stock had its "hold" rating restated by research analysts at Needham & Company LLC in a research note issued on Thursday,Benzinga reports.

Several other analysts have also recently weighed in on the stock. Bank of America decreased their price objective on shares of Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating on the stock in a research note on Thursday. Stifel Nicolaus decreased their price target on shares of Bausch + Lomb from $19.00 to $18.00 and set a "hold" rating on the stock in a research note on Wednesday, January 29th. Royal Bank of Canada decreased their price target on shares of Bausch + Lomb from $23.00 to $22.00 and set an "outperform" rating on the stock in a research note on Wednesday, January 29th. Morgan Stanley cut shares of Bausch + Lomb from an "overweight" rating to an "equal weight" rating and set a $19.00 price target on the stock. in a research note on Monday, December 2nd. Finally, HC Wainwright reissued a "buy" rating and set a $23.00 price target on shares of Bausch + Lomb in a research note on Tuesday. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $19.83.

Bausch + Lomb Price Performance

Bausch + Lomb stock traded down $0.15 during trading hours on Thursday, hitting $15.75. 589,710 shares of the stock were exchanged, compared to its average volume of 684,586. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.57. The stock has a market capitalization of $5.55 billion, a P/E ratio of -17.30, a P/E/G ratio of 2.17 and a beta of 0.46. Bausch + Lomb has a 12 month low of $13.16 and a 12 month high of $21.69. The business's 50-day moving average is $17.36 and its two-hundred day moving average is $18.13.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its quarterly earnings data on Wednesday, February 19th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.02. The firm had revenue of $1.28 billion for the quarter, compared to analysts' expectations of $1.26 billion. Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.34%. The company's quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.24 earnings per share. Equities research analysts expect that Bausch + Lomb will post 0.79 EPS for the current fiscal year.

Hedge Funds Weigh In On Bausch + Lomb

Large investors have recently bought and sold shares of the business. Blue Trust Inc. lifted its holdings in Bausch + Lomb by 68.3% in the fourth quarter. Blue Trust Inc. now owns 2,474 shares of the company's stock valued at $48,000 after buying an additional 1,004 shares during the period. FNY Investment Advisers LLC acquired a new stake in Bausch + Lomb in the fourth quarter worth $72,000. Commonwealth Equity Services LLC acquired a new stake in Bausch + Lomb in the fourth quarter worth $181,000. Alpine Global Management LLC acquired a new stake in Bausch + Lomb in the fourth quarter worth $181,000. Finally, Covestor Ltd acquired a new stake in Bausch + Lomb in the fourth quarter worth $188,000. 11.07% of the stock is currently owned by institutional investors and hedge funds.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.